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Summary
To	achieve	WHO	hepatitis	C	virus	(HCV)	elimination	targets	by	2030,	mathematical	
models	suggest	there	needs	to	be	significant	scale-	up	of	treatment	among	people	who	
inject	drugs	(PWID).	We	tested	whether	people	who	actively	inject	drugs	can	be	re-
cruited	and	treated	successfully	through	a	community	needle	and	syringe	programme	
(NSP),	 and	assessed	 rates	of	 re-	infection.	105	HCV	RNA	positive	participants	were	
enrolled	prospectively.	Participants	were	recruited	from	the	 largest	NSP	 in	Dundee	
over	42	months.	94/105	individuals	commenced	treatment.	Genotype	1	(G1)	individu-
als	 (n	=	37)	 were	 treated	 with	 peg-	interferon+ribavirin+Simepravir/Telaprevir.	
Genotype	2/3	 (G2/3)	 (n	=	57)	received	peg-	interferon+ribavirin.	Weekly	study	visits	
took	place	within	the	NSP.	Mean	age	of	participants	was	34.0	years	(SD	6.9),	71.3%	
(61/94)	were	male.	One	in	five	(20/94)	participants	were	homeless.	68.1%	(64/94)	were	
on	OST	(opiate	substitution	therapy)	at	enrolment;	participants	 injected	median	6.5	
times/wk.	In	terms	of	clinical	outcomes,	>80%	treatment	adherence	was	71.3%	(67/94).	
There	was	no	difference	in	SVR-	12	rates	by	genotype:	81.0%	(30/37)	for	G1	and	82.5%	
(47/55)	for	G2/3.	At	18	months	post-	treatment,	15/77	participants	were	reinfected,	
followed	up	over	69.8	person-	years,	yielding	a	re-	infection	rate	of	21.5/100	person-	
years	(95%	CI	13.00-	35.65).	This	trial	demonstrates	that	HCV	treatment	can	be	deliv-
ered	successfully	to	the	target	population	of	treatment	as	prevention	strategies.	We	
report	higher	rates	of	re-	infection	than	existing	estimates	among	PWID.	Scale-	up	of	
HCV	 treatment	 should	be	pursued	alongside	a	 comprehensive	programme	of	harm	
reduction	interventions	to	help	minimize	re-	infection	and	reduce	HCV	transmission.
K E Y W O R D S
hepatitis	C	virus,	injecting	drug	use,	people	who	inject	drugs,	re-infection,	treatment	as	
prevention
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1  | INTRODUC TION
The	global	burden	of	hepatitis	C	virus	(HCV)-	related	liver	disease	
continues to rise.1	 In	 2010,	 the	 number	 of	 deaths	 due	 to	 HCV	
was	 estimated	 to	 be	 500	000	 worldwide.2	WHO	 targets	 are	 to	
eliminate	HCV	by	2030.3	 In	Scotland,	over	90%	of	new	HCV	 in-
fections	occur	among	people	who	inject	drugs	(PWID).4	HCV	an-
tibody	prevalence	among	PWID	is	58%,	similar	to	other	European	
countries.5,6
In	 2016,	 1.76	million	 of	 the	 71	million	 people	 living	 with	
HCV	 worldwide	 received	 treatment	 (~2.48%	 treatment	 uptake).7 
Treatment	 uptake	 has	 been	 historically	 low	 among	PWID	prior	 to	
the	introduction	of	new	direct-	acting	antivirals	(DAA)	treatments.8 
However,	 there	 is	now	good	evidence	 that	HCV	 treatment	 is	 safe	
and	 effective	 among	 PWID.9-12	 The	 latest	 international	 guide-
lines13,14	now	recommend	treatment	for	all	PWID.	However,	 latest	
data	from	Hep-	CORE	study	found	8/25	(32%)	of	European	countries	
surveyed	continue	to	refuse	treatment	to	PWID.15
Treating	 active	 PWID	 also	 has	 the	 potential	 to	 reduce	 HCV	
transmission,	 a	 concept	 known	 as	 treatment	 as	 prevention	 (TasP).	
Modelling	 data	 suggest	 that	 scaling-	up	 treatment	 among	 current	
PWID	with	DAAs	is	critical	to	reducing	HCV	prevalence,16-18 and is 
F IGURE  1 Flow	diagram	of	cohort	recruitment	into	Eradicate	study
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cost-	effective	in	settings	such	as	the	UK	with	moderate	HCV	prev-
alence.19	Reductions	in	prevalence	are	greater	when	combined	with	
scale-	up	of	harm	reduction	interventions—opioid	substitution	therapy	
(OST)	and	high	coverage	Needle	and	Syringe	Programmes	(NSP).20-22 
Recent	modelling	of	the	Scottish	epidemic	attributed	55%	of	the	re-
duction	in	HCV	incidence	from	14.2/100	pyrs	in	2008	to	5.5/100	in	
2015	to	national	scale-	up	of	harm	reduction	interventions.21
To	date,	studies	assessing	HCV	treatment	success	among	PWID	
have	recruited	from	populations	engaged	in	hepatology	or	special-
ist addiction services.9,10,23,24	These	studies	define	“active	injecting	
drug	 use”	 as	 those	who	 have	 injected	 in	 the	 last	 6	 or	 12	months,	
and	many	 require	 a	 period	 of	 abstinence	 from	 injecting	 drug	 use	
(IDU)	prior	to	starting	treatment.	These	are	therefore	populations	of	
largely	stable	PWID,	at	low	risk	of	transmitting	HCV.	To	achieve	the	
greatest	reduction	in	HCV	incidence,	treatment	programmes	should	
target	PWID	who	are	most	 likely	 to	 transmit	 the	virus.	This	 is	 the	
study population we aimed to recruit.
In	 this	 study,	we	aimed	 to	 test	whether	100	people	who	were	
currently	injecting	drugs	could	be	recruited	and	successfully	treated	
for	HCV	in	a	NSP.	We	also	assessed	rates	of	re-	infection.	The	sec-
ondary	aims	were	to	identify	factors	associated	with	treatment	ad-
herence,	re-	infection	and	cure.
2  | METHODS
2.1 | Study design and cohort recruitment
Eradicate was a prospective observational study conducted at the 
largest	Needle	and	Syringe	Programme	(NSP)	in	Dundee,	Scotland.	
Participants	were	recruited	between	December	2012	and	July	2016	
(Figure	1).	Since	2009,	all	PWID	attending	the	central	NSP	in	Dundee	
(range	 1280-	2118	 anonymous	 individuals	 per	 year	 between	 2012	
and	 2016)	were	 offered	 yearly	 dried	 blood	 spot	 testing	 (DBS)	 for	
blood-	borne	viruses	 (BBV)	 (range	123-	203	 identified	PWID	tested	
per	year	2009-	2016).	During	the	study	enrolment	period,	all	PWID	
who	tested	positive	for	HCV	and	fulfilled	study	enrolment	criteria	
(Table	1)	were	 invited	 to	 participate.	Only	 individuals	who	had	 in-
jected	in	the	past	week	were	eligible	for	the	study.	Recruitment	was	
carried	 out	 by	 on-	site	 research	 nurses.	 All	 participants	who	were	
not	already	prescribed	OST	were	offered	low-	threshold	methadone	
treatment	 at	 enrolment.	 This	was	defined	 as	 low-	threshold	 as	 the	
primary	goal	was	improved	HCV	treatment	adherence,	not	complete	
abstinence.25	Each	participant	was	offered	naloxone	training,	as	rec-
ommended	by	clinical	guidelines.26	All	participants	provided	written	
informed	consent.	Ethical	 approval	was	obtained	 from	the	East	of	
Scotland Research Ethics committee.
2.2 | HCV treatment
HCV	 treatment	 followed	 standard	 NHS	 clinical	 practice	 at	 the	
time	 of	 study	 enrolment.	 Individuals	 were	 treated	 with	 peg-	
interferon+ribavirin+/−	protease	inhibitor	for	12,	16	or	24	weeks	
(see	 Appendix	 S1).	 During	 treatment,	 patients	 attended	 weekly	
study	visits	at	the	NSP.	At	each	weekly	visit,	participants	received	
an	interferon	injection	and	a	week’s	supply	of	tablets.	Participants	
who were subsequently in prison had medication delivered weekly.
2.3 | Data collection
At	enrolment	(visit	1),	participants	completed	a	questionnaire	com-
prising	of:	demographics;	social	history	(current	living	situation,	em-
ployment,	 incarceration);	 medical	 and	 psychiatric	 history;	 alcohol	
and	drug	use;	and	injecting	practices.	Baseline	bloods	including	viral	
load,	genotyping,	HIV,	hepatitis	B,	full	blood	count,	ferritin,	urea	&	
electrolytes,	liver	function	tests	were	obtained	and	level	of	fibrosis	
level	was	assessed	using	Fibroscan	or	Fib4	scores.	At	visit	2,	partici-
pants commenced treatment.
Prior	 to	 treatment	 commencement	 participants	 completed	 the	
EuroQol-	5	Dimensions	questionnaire	(EQ-	5D-	3L).27	Participants	were	
assessed	weekly	for	adverse	events,	which	were	managed	as	per	local	
standard	clinical	practice.	At	each	visit,	participants	were	given	a	£5	
supermarket	voucher	(contingency	management)	and	week	supply	of	
protein	drinks.	Monitoring	bloods	were	taken	weekly	for	the	first	four	
weeks,	then	fortnightly	until	end	of	treatment.	HCV	RNA	was	obtained	
at	week	4	(to	determine	rapid	virological	response),	week	12	and	end	of	
treatment.	Participants	were	PCR	tested	post-	treatment	to	determine	
sustained	virological	response	at	12	weeks	(SVR-	12),	and	at	6-	and	18-	
month	post-	treatment	to	determine	re-	infection.
2.4 | Study outcomes and analysis
Three	primary	outcomes	were	assessed:	 (a)	successful	recruitment	
of	our	target	population	into	the	study;	(b)	proportion	who	achieved	
SVR-	12;	 (c)	 re-	infection	 rate.	All	positive	post-	treatment	PCR	RNA	
TABLE  1  Inclusion	and	exclusion	criteria	for	Eradicate	study
Inclusion criteria
1.	Age	18-	70	y
2.	Active	HCV	positive	infection	confirmed	with	PCR
3.	Current	injecting	drug	use	established	through	review	of	needle	
injection sites and patient history
4.	If	female,	negative	urine	test	for	pregnancy	and	on	Long-	Acting	
Reversible	Contraception	during	study
Exclusion criteria
1.	Aggressive	or	violent	behaviour
2.	Features	of	decompensated	liver	failure
3.	Evidence	of	primary	hepatocellular	carcinoma
4.	Pregnancy,	breastfeeding	or	pre-	menopausal	female	not	using	
effective	contraception
5.	Contraindications	to	peg-	interferon	or	Ribavirin
6.	Previous	treatment	with	peg-	interferon	and	Ribavirin
7.	Participation	in	a	drug	study	within	previous	30	d
8.	Inability	to	provide	informed	consent
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results	 were	 genotyped	 to	 determine	whether	 this	 represented	 a	
new	HCV	strain.	Re-	infection	was	defined	as	a	positive	PCR	result	at	
6-	or	18-	month	post-	treatment,	for	individuals	who	achieved	SVR-	
12.	The	secondary	outcome	was	 treatment	adherence.	Adherence	
was	defined	using	the	“80/80/80	rule”:	participants	must	complete	
80%	interferon	injections	and	80%	ribavirin	tablets	for	80%	of	the	
treatment	duration.	At	each	 study	visit,	 patients	 returned	any	un-
used	tablets	from	the	previous	week	to	estimate	weekly	medication	
compliance.
2.4.1 | EQ5D
The	 EQ5D-	5D-	3L	 is	 a	 standardized	 questionnaire	 which	 assesses	
quality	of	life	(QoL)	in	five	dimensions.	It	is	widely	used	to	measure	
health	 states	 among	 this	 population.28,29	 During	 analysis,	 a	 single	
summary	QoL	 index	 value	 for	 each	 participant	was	 derived	 using	
country-	specific	EQ-	5D	value	sets	and	a	known	algorithm.30	These	
were	then	compared	to	latest	UK	population	norms	by	age	and	sex.31
2.4.2 | SVR and adherence
Univariable	logistic	regression	was	performed	to	determine	factors	
associated	with	treatment	adherence.	Predictor	variables	decided	a	
priori23,32	 included	age,	 sex,	on	OST	 treatment,	 length	HCV	treat-
ment,	 incarceration	 during	 treatment,	 homelessness,	 living	 with	
other	 PWID,	 history	 of	 anxiety	 and	 depression	 and	 injecting	 fre-
quency.	 Logistic	 regression	was	 also	 used	 to	 assess	 predictors	 of	
SVR-	12.	Factors	were	based	on	known	predictors	of	SVR-	12	 from	
existing	literature.23,32-34	These	included	treatment	adherence,	age,	
sex,	 fibrosis	 score,	 HCV	 genotype	 and	 pre-	treatment	 HCV	 RNA	
level.	We	 hypothesized	 that	 OST	 treatment,	 homelessness,	 incar-
ceration,	living	with	other	PWID,	history	of	anxiety	and	depression	
and	injecting	frequency	may	also	be	associated	with	attainment	of	
SVR-	12.	However,	any	association	would	be	mediated	through	their	
impact	on	adherence;	therefore,	they	were	not	included	in	the	SVR-	
12	logistic	regression	analysis.
2.4.3 | Re- infection rate
The	incidence	of	re-	infection	is	expressed	in	person-	years.	Time	at	
risk	began	following	attainment	of	SVR-	12	and	ended	at	date	of	re-	
infection	or	date	of	 last	negative	PCR	 test	 (if	 not	 reinfected).	The	
time	at	which	 re-	infection	occurred	was	estimated	 to	be	 the	mid-	
point	between	the	 last	negative	and	first	positive	PCR	result.	One	
participant	had	become	reinfected	at	3	months	(PCR	negative	at	end	
of	treatment,	PCR	positive	at	3	months	with	different	genotype).	For	
this participant, the time- at- risk period was the mid- point between 
end-	of-	treatment	 and	 SVR-	12.	 Participants	 who	 did	 not	 achieve	
SVR-	12	or	who	died	prior	to	6-	month	PCR	test	were	excluded	from	
estimates	of	 re-	infection.	 Participants	who	were	 lost	 to	 follow-	up	
were	censored	at	the	last	post-	treatment	PCR	test	obtained.	Six	pa-
tients	were	 not	 yet	 18-	month	 post-	treatment	 and	were	 therefore	
censored	at	6	months.
Poisson	regression	assessed	factors	associated	with	re-	infection	
rate.	These	included	age,	sex,	on	OST	treatment,	homelessness,	liv-
ing	with	other	PWID,	history	of	anxiety	and	depression	and	injecting	
frequency.35,36	All	analysis	was	performed	in	STATA.
3  | RESULTS
3.1 | Recruitment and baseline characteristics
A	 total	of	724	 individuals	were	 tested	 for	HCV	at	 the	Needle	 and	
Syringe	Programme	(NSP)	during	study	enrolment	period	(Figure	1).	
Of	these,	145/724	(20.0%)	were	HCV	antibody	positive	on	DBS	test-
ing,	with	92	positive	on	PCR	RNA	testing.	Of	these	newly	diagnosed	
individuals,	 69/92	were	 recruited	 into	 the	 study.	36	 individuals	 al-
ready	known	to	be	positive	from	previous	testing	were	also	recruited.	
This	gives	a	total	of	105	individuals	were	enrolled	into	the	study,	with	
94	participants	ultimately	commencing	treatment	(Figure	1).
For	participants	commencing	treatment	(n	=	94),	mean	age	was	
34	 (SD	 6.9)	 years;	 the	majority,	 71.3%	 (67/94),	 were	male;	 1	 in	 5	
participants	 were	 homeless	 or	 living	 in	 unstable	 accommodation	
(20/94);	and	12.8%	(12/94)	were	in	prison	at	some	point	during	the	
treatment	period	(Table	2).	Reported	history	of	anxiety/depression	
was	 high,	 69.2%	 (65/94),	 and	 37/94	 (39.4%)	 reported	 a	 previous	
suicide	 attempt.	Median	 injecting	 frequency	was	 6.5	 times/week;	
54.3%	 (51/93)	 participants	 injected	 daily/more	 than	 once	 a	 day.	
Reported	alcohol	consumption	was	comparatively	low:	9.6%	(9/94)	
consumed	alcohol	>3	times	a	week.
Median	health	 utility	was	0.72	 (IQR	0.41-	0.85)	 on	EQ5D,	with	
nearly	 ¾	 (74%)	 of	 the	 study	 population	 reporting	 a	 health	 utility	
below	the	25th	percentile,	when	compared	to	the	general	UK	pop-
ulation	of	a	similar	age	and	sex.31	In	terms	of	harm	reduction	inter-
ventions;	the	majority,	82.4%	(75/91),	had	100%	needle	and	syringe	
provision	(1	or	more	needles	obtained	from	NSP	for	each	injection	
reported),37	 and	 62.5%	 (55/88)	were	 receiving	 opiate	 substitution	
therapy	 (OST)	 prior	 to	 enrolment	 (with	 a	 further	 11	 participants	
commenced	on	OST	at	enrolment).	39.4%	(37/94)	were	genotype	1	
(G1),	60.6%	(57/94)	genotype	2/3	(G2/3).	Levels	of	significant	fibro-
sis	 (F2-	F4)	were	 low;	17/94	 (18.1%).	All	participants	were	HIV	and	
hepatitis	B	negative.
3.2 | Treatment outcomes
Overall,	 82%	 (77/94)	 participants	 achieved	SVR-	12	 (Appendix	 S2).	
There	was	no	difference	in	SVR12	rates	between	genotype:	81.0%	
(30/37)	for	G1	and	82.5%	(47/57)	for	G2/3.	71.3%	(67/94)	individu-
als	achieved	≥80%	treatment	adherence	(Table	3).	Reasons	for	non-	
adherence	are	available	for	15/27	participants;	eight	missed	multiple	
appointments,	four	were	admitted	to	hospital	with	injecting-	related	
health	problems	and	advised	to	stop	treatment;	two	withdrew	from	
treatment	 due	 to	 deteriorating	mental	 health;	 one	 died	 from	 sus-
pected	drug	overdose.	Of	the	64/94	participants	on	OST	at	enrol-
ment,	 the	 majority,	 93.8%	 (60/64),	 remained	 on	 OST	 during	 the	
treatment	 period.	 All	 participants	 attended	 follow-	up	 at	 6-	month	
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post-	treatment.	 At	 18	months,	 nine	 participants	 had	 been	 lost	 to	
follow-	up	(Figure	2).
In	 total,	 eight	 participants	 had	 died	 by	 18-	month	 follow-	up.	
Cause	of	death	is	available	in	5/8	cases;	four	participants	died	from	
suspected	drug	overdose,	one	participant	died	of	septicaemia	sec-
ondary	to	injection	of	drugs.	This	gives	an	overall	mortality	rate	of	
5.55/100	 person-	years	 (95%	 CI	 2.77-	11.09)	 during	 treatment	 and	
follow-	up	period	(total	follow-	up	time	144.24	years).
3.3 | Predictors of treatment adherence and SVR- 12
Longer	 treatment	 length	 (24	weeks	 vs	 12/16	weeks)	 was	 associ-
ated	with	reduced	treatment	adherence,	OR	0.35	(95%	CI	0.13-	0.98)	
(P	=	0.047)	(Table	4).	Remaining	on	OST	during	the	study	was	weakly	
associated	with	 increased	 adherence,	OR	2.03	 (95%	CI	 0.82-	5.08)	
(P	=	0.13).	There	was	no	convincing	evidence	of	an	association	be-
tween	adherence	and	other	hypothesized	factors;	age,	sex,	unstable	
housing,	 incarceration,	 living	 with	 other	 drug	 users,	 injecting	 fre-
quency,	history	anxiety/depression.	Therefore,	multivariable	analy-
sis	was	not	performed.
In	 univariable	 analysis,	 a	 greater	 proportion	 of	 treatment	 ad-
herent	 participants	 achieved	 SVR	 (OR	 7.00,	 95%	 CI	 2.24-	21.8,	
P	<	0.001)	 (Appendix	 S3).	 Age,	 sex,	 fibrosis	 level,	 PCR	 RNA	 level	
and	genotype	did	not	 independently	predict	 achievement	of	SVR-	
12.	In	adjusted	analysis,	with	all	variables	from	unadjusted	analysis	
included in model, adherence remained positively correlated with 
achieving	SVR	(P	<	0.001).
3.4 | Re- infection rate
At	 six	months,	 5/77	 participants	 who	 achieved	 SVR-	12	 had	 be-
come	reinfected	yielding	a	re-	infection	rate	of	23.53/100	person-	
years	 (95%	 CI	 9.80-	56.54).	 The	 total	 follow-	up	 time	 was	 21.25	
person-	years.	At	18	months,	 there	were	15/77	re-	infections	giv-
ing	a	cumulative	18-	month	re-	infection	rate	of	21.49/100	person-	
years	 (95%	 CI	 13.00-	35.65)	 over	 total	 follow-	up	 time	 69.79	
person- years.
Unadjusted	 analysis	 found	 age	 <30	years	 was	 weakly	 associ-
ated	with	a	higher	 re-	infection	rate	 (vs	30-	40	years,	P	=	0.063)	 (vs	
>40	years,	P	=	0.14).	There	was	no	evidence	of	correlation	between	
other	hypothesized	factors	(Table	4).	Therefore,	we	did	not	perform	
multivariable	regression.
4  | DISCUSSION
4.1 | Main findings
We	show	that	it	is	feasible	to	recruit	people	who	inject	drugs	(PWID)	
from	a	community-	based	needle	and	syringe	programme	(NSP)	onto	
HCV	treatment,	and	achieve	over	80%	SVR-	12	and	impressive	treat-
ment	adherence	(even	with	older	regimens).	Re-	infection	rates,	how-
ever,	in	this	population	were	high	at	21.5/100	person-	years	(95%	CI	
TABLE  2 Baseline	characteristics	of	study	population
Characteristic n = 94 %
Demographics
Age,	mean	(SD)	(range),	years 34.0	(6.9)	(21-	49)
Male 67 71.3
Living	situation	and	employment
Owned	or	rented	housing 67 71.3
Homeless/unstable	housinga 20 21.3
Living	with	other	PWID 34 37.0
Unemployed 88 93.6
Incarcerationb 12 12.8
Current	drug	and	alcohol	use
Opiates 93 98.9
Benzodiazepines 55 58.5
Legal	highs 13 13.8
Gabapentin/Pregabalin 38 40.4
Cannabis 57 60.6
Amphetamines 5 5.3
Consume	alcohol	>3	time	a	week 9 9.6
Injecting	practices
No.	years	injectingc,	mean	(SD)	(IQR) 9.7	(7.0)	(5-	13)
No.	times	injected	in	past	weekd, 
median	(SD)	(IQR)
6.5	(9.3)	(2-	14)
Inject	daily/more	than	once	a	dayd,e 51 54.3
No.	clean	needles	obtained	per	
weekf	median	(SD)	(IQR)
10	(19.2)	(5-	20)
Harm	reduction	coverage
100%	needle	and	syringe	provisionf,g 75 82.4
On	OST	prior	to	enrolmenth 55 62.5
Mental	and	social	health
EQ5D	health	utility,	median	(IQR) 0.72	(0.41-	0.85)
History	anxiety/Depression 65 69.2
Previous	suicide	attempt 37 39.4
Clinical	measures
HCV	Genotype
1 37 39.4
2/3 57 60.6
Significant	fibrosis	(F2-	F4)i 17 18.1
HCV	RNA	(IU/mL),	median	(IQR) 440	000	(61	000,	
1	700	000)
aTemporary/unstable	accommodation/hostel/sofa	surfing.	
bIn	prison	for	part	or	all	of	treatment	period.	
cFour	participants	did	not	wish	to	answer	(n	=	90).	
dOne	participant	did	not	wish	to	answer	(n	=	93).	
eDuring	an	average	month	of	injecting.	
fThree	participants	did	not	wish	to	answer	(n	=	91).	
gOne	or	more	needles	obtained	from	a	needle	exchange	centre	for	each	
injection reported. 
hMissing	data	for	six	participants	(n	=	88).	
iUsing	baseline	Fibroscan	scores	or	FIB-	4	index	for	patients	who	did	not	
have Fibroscan results. 
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13.00-	35.65)	 at	 18-	month	 post-	treatment.	 Mortality	 rates	 in	 our	
population	also	were	high.
4.2 | Strengths and limitations
This	is	the	first	HCV	treatment	study,	to	our	knowledge,	in	which	all	
enrolment,	treatment	and	follow-	up	took	place	in	the	community	at	
a	Needle	and	Syringe	Programme	(NSP)	and	that	active	injecting	was	
an	inclusion	criteria.	This	model	achieved	high	levels	of	HCV	testing	
and	treatment	uptake	among	active	injectors,	with	very	low	loss	to	
follow-	up.	The	study	population	is	unique;	at	enrolment,	all	partici-
pants	had	injected	within	the	past	week	representing	a	highly	active	
population	of	injectors.
The	study	has	several	limitations.	First,	it	was	a	small-	scale	pilot	
study	 involving	94	participants,	based	 in	one	NSP	 in	Dundee.	The	
size	of	the	study	meant	there	was	insufficient	power	to	identify	inde-
pendent	predictors	of	adherence,	SVR-	12	and	re-	infection.	Injecting	
risk	patterns	following	SVR-	12	were	unavailable	which	also	limited	
analysis	of	predictors	of	re-	infection.	Second,	recruitment	began	be-
fore	the	shift	in	clinical	practice	from	interferon-	based	treatment	to	
DAAs—though	even	with	older	regimens	very	high	rates	of	SVR-	12	
were	achieved.	We	expect	that	higher	rates	of	cure	should	be	pos-
sible	with	more	effective,	better	 tolerated	DAAs.	Third,	 follow-	up	
positive	PCR	results	were	genotyped	to	distinguish	between	relapse	
and	 re-	infection.	 Gold	 standard	 would	 be	 sequencing	 to	 confirm	
re-	infection.
4.3 | Comparison to existing literature and 
implications
This	 study	 reports	 rates	 of	 re-	infection	 following	 treatment	 that	
are	 significantly	higher	 than	existing	estimates	among	PWID.	Two	
meta-	analyses	estimate	a	pooled	re-	infection	rate	among	PWID	of	
TABLE  3 HCV	treatment	adherence,	sustained	viral	response,	
re-	infection	and	deaths
Genotype G1 G2/3 Total
Study outcome N % n % n %
Genotype 37 39.4 57 60.6 94 100
SVR- 12a 30 81.0 47 82.5 77 81.9
≥80%	treatment	
adherence
67 71.3
Re-	infections	at	
6	mob
5
Re-	infections	at	
18 mob
15
Deaths	at	6	mo 3
Deaths at 18 mo 8
aSVR-	12:	sustained	virological	response	at	12	wk.	
bCumulative	number	of	re-	infections.	
F IGURE  2 Flow	diagram	of	study	outcomes	at	3-	mo,	6-	mo	and	18-	mo	follow-	up
94 Individuals 
commenced 
treatment
77 Achieved 
SVR-12
17 did not achieve SVR12
14 relapsed (positive 
PCR RNA at 12 wks)
2 Died 
1 re-infection
4 new re-infections 
at 6-months
1 Died
3 mo 6 mo
72 Remained 
PCR negative
42 Remained 
PCR negative
10 new re-infections at 
18-months
5 Died
1 Declined PCR test
9 Did not attend
6 not yet due for 18-
month follow-up
18 mo
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1.77/100	pyrs	 to	 2.4/100	pyrs.10,38	 Though	 recent	 studies	 report	
greater	 re-	infection	 rates	 among	 higher	 risk	 populations;	 4.9/100	
person-	years	 among	 relapsed	 PWID39	 to	 5.7/100	 person-	years	
among	individuals	hospitalized	for	a	drug-	related	cause.35	However,	
all these studies10,35,36,38-43	 defined	 “active	 PWID”	 as	 those	 who	
have	“injected	in	the	past	6-	or	12-	months”—except	Hilsden	et	al44 
who	defined	“active”	as	having	injected	in	the	past	3	months,	with	a	
reported	 re-	infection	 rate	of	2.8/100	person-	years.	 This	 is	 signifi-
cantly	different	to	our	study	population,	all	of	whom	had	injected	in	
the	past	week	and	the	majority	were	injecting	daily.
In	fact,	these	re-	infection	rates	are	closer	to	latest	estimates	of	
HCV	incidence	among	recent	injectors	(past	6	months)	in	Scotland	
at	 12.4/100	pyrs	 (CI	 6.8-	19.5)	 in	 2015/2016.45	 This	 has	 two	 im-
plications.	 First,	 the	 evidence	 supports	 a	 critical	 assumption	 of	
impact and economic models that there may be no additional be-
haviour	 change	 following	HCV	 treatment	 (over	 and	 above	 expo-
sure	 to	 other	 interventions)	 and	 re-	infection	 rates	 are	 similar	 to	
HCV	incidence	in	the	community.16,17,19	Second,	the	high	HCV	in-
cidence	and	re-	infection	rates	highlight	the	failure	of	current	cov-
erage	 and	 intensity	 of	 harm	 reduction	 interventions	 to	minimize	
injecting	risk.
This	high	re-	infection	rate,	along	with	a	significant	mortality	rate	
(5.55/100	 person-	years)	 and	 high	 level	 of	 incarceration	 (12.8%	 in	
prison	at	some	point	during	study	period),	indicate	this	is	an	unstable	
population	who	would	benefit	from	a	broader	programme	of	social	
and	 psychological	 interventions—alongside	 NSP	 and	 OST	 provi-
sion—to	reduce	injecting	risk,	as	recommended	by	recent	UK	clinical	
guidelines.26	Once	treated,	at-	risk	individuals	should	continue	to	be	
regularly	tested	for	re-	infection	and	retreated	 if	active	 infection	 is	
detected,	as	per	latest	international	guidelines.14	At	the	time	of	writ-
ing	this	paper,	10/15	of	reinfected	participants	are	currently	being	
retreated or have completed retreatment.
SVR-	12	 rates	 are	 higher	 than	 reported	 rates	 among	 PWID	 for	
these	drugs	in	the	literature.10,32	This	may	be	due	to	several	factors.	
The	 study	 population	 is	 on	 average	 younger,	 with	 lower	 fibrosis	
scores	and	 lower	 initial	HCV	RNA	 levels	compared	to	 those	 in	ex-
isting	studies.10,32	These	are	well-	described	factors	associated	with	
higher	 cures	 for	 interferon,	 ribavirin	 and	 first-	generation	protease	
inhibitors.	 Health-	related	 quality	 of	 life	 was	 low,	 in	 keeping	 with	
previous	studies	among	HCV+	populations	and	PWIDs.28,46	Overall,	
treatment	 adherence	was	 71.3%,	 slightly	 lower	 than	 has	 been	 re-
ported in literature.10,32	However,	these	data	remain	impressive	con-
sidering	 this	 is	a	highly	active	 injecting	population	with	significant	
rates	 of	 homelessness,	 incarceration	 and	mental	 health	 problems.	
Weekly	nurse-	led	follow-	up	visits	and	use	of	contingency	manage-
ment	may	have	 influenced	adherence.	The	 results	 add	 to	 growing	
evidence	that	HCV	treatment	can	be	successfully	provided	through	
community- based models.9,10,23,24,44,47
Our	 results	 demonstrate	 some	 association	 between	 OST	 and	
higher	 rates	 of	 adherence.	 This	 is	 consistent	with	 findings	 from	 a	
previous meta- analysis,32	with	implications	for	the	role	of	addiction	
treatment	alongside	HCV	care.	Shorter	treatment	duration	was	as-
sociated	with	improved	adherence	(12/16-	vs	24-	weeks)	(P	=	0.047).	
This	has	important	implications	for	adherence	on	current	DAA	treat-
ment	 regimens	 which	 are	 now	 only	 8-	 or	 12-	weeks.	 Re-	infection	
rate	 decreased	with	 age	 (P	=	0.063),	 consistent	with	 existing	 liter-
ature.36,39	There	was	little	association	between	other	hypothesized	
factors	and	adherence	or	re-	infection.
5  | CONCLUSION
PWID	were	successfully	recruited,	treated	and	followed	up	from	a	
community	NSP.	However,	we	also	report	higher	rates	of	re-	infection	
than	many	other	studies.	This	demonstrates	that	we	have	success-
fully	engaged	with	and	treated	a	high-	risk	injecting	population	who	
should	be	targeted	as	part	of	any	successful	treatment	as	prevention	
(TasP)	strategy.	Scaling-	up	the	intensity	of	harm	reduction	and	HCV	
treatment	provision	 is	needed	to	minimize	re-	infection	and	reduce	
HCV	transmission	in	the	population.
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